eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.
Research ArticlePharmacology
A G protein–biased S1P1 agonist, SAR247799, protects endothelial cells without affecting lymphocyte numbers
- View ORCID ProfileBruno Poirier1,
- View ORCID ProfileVeronique Briand1,
- Dieter Kadereit2,*,
- Matthias Schäfer3,
- View ORCID ProfilePaulus Wohlfart3,
- Marie-Claire Philippo1,
- View ORCID ProfileDominique Caillaud1,
- View ORCID ProfileLaurent Gouraud1,
- Patrick Grailhe1,
- View ORCID ProfileJean-Pierre Bidouard1,
- Marc Trellu4,
- Anthony J. Muslin5,
- Philip Janiak1, and
- View ORCID ProfileAshfaq A. Parkar6,†
- 1Diabetes and Cardiovascular Research, Sanofi R&D, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France.
- 2Medicinal Chemistry, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main,, Germany.
- 3Diabetes and Cardiovascular Research, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
- 4Drug Metabolism and Pharmacokinetics, Sanofi R&D, 1 Avenue Pierre Brossolette, 91385 Chilly-Mazarin, France.
- 5Diabetes and Cardiovascular Research, Sanofi US Services, 640 Memorial Drive, Cambridge, MA 02139, USA.
- 6Diabetes and Cardiovascular Research, Sanofi US Services, 55 Corporate Drive, Bridgewater, NJ 08807, USA.
- ↵†Corresponding author. Email: ashfaqaparkar{at}gmail.com
↵* Present address: Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riß, Germany.
See allHide authors and affiliations
Science Signaling 02 Jun 2020:
Vol. 13, Issue 634, eaax8050
DOI: 10.1126/scisignal.aax8050
Vol. 13, Issue 634, eaax8050
DOI: 10.1126/scisignal.aax8050
Bruno Poirier
1Diabetes and Cardiovascular Research, Sanofi R&D, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France.
Veronique Briand
1Diabetes and Cardiovascular Research, Sanofi R&D, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France.
Dieter Kadereit
2Medicinal Chemistry, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main,, Germany.
Matthias Schäfer
3Diabetes and Cardiovascular Research, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
Paulus Wohlfart
3Diabetes and Cardiovascular Research, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
Marie-Claire Philippo
1Diabetes and Cardiovascular Research, Sanofi R&D, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France.
Dominique Caillaud
1Diabetes and Cardiovascular Research, Sanofi R&D, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France.
Laurent Gouraud
1Diabetes and Cardiovascular Research, Sanofi R&D, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France.
Patrick Grailhe
1Diabetes and Cardiovascular Research, Sanofi R&D, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France.
Jean-Pierre Bidouard
1Diabetes and Cardiovascular Research, Sanofi R&D, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France.
Marc Trellu
4Drug Metabolism and Pharmacokinetics, Sanofi R&D, 1 Avenue Pierre Brossolette, 91385 Chilly-Mazarin, France.
Anthony J. Muslin
5Diabetes and Cardiovascular Research, Sanofi US Services, 640 Memorial Drive, Cambridge, MA 02139, USA.
Philip Janiak
1Diabetes and Cardiovascular Research, Sanofi R&D, 1 Avenue Pierre Brossolette, 91385 Chilly Mazarin, France.
Ashfaq A. Parkar
6Diabetes and Cardiovascular Research, Sanofi US Services, 55 Corporate Drive, Bridgewater, NJ 08807, USA.
Submit a Response to This Article
No eLetters have been published for this article.